Pipetting Samples
Line separator

CLINICAL TRIALS FUNDED

AWARD LIST.

Beginning during the fiscal year 2015-2016 Cancer League of Colorado’s Board of Directors approved funding of Investigator Initiated Clinical Trials. As of July 2020 the following Trials have been funded:
Jose M. Pacheco, MD

July, 2020

$50,000

A Pilot Study of Temozolomide in combination with Osimertinib or Lorlatinib in NSCLC patients with CS Progression on either Osimertinib or Lorlatinib

Ashley E. Glode, PharmD, BCOP

June, 2020

$15,000

Expansion and Evaluation of the University of Colorado STRENGTH (Striving to Reactivate Esophageal and Gastric Health) Rehabilitation Program

Sana Karam, MD

December, 2019

$100,000

A Phase 1b Study of sEpdBr-HAS in Combination with Cetuximab and Radiation Therapy in Patients with EGFR-Expressing Locally-Advanced Squamous Cell Carcinomas of the Head and Neck and Heavy Smoking Histories

Jessica McDermott, MD

July, 2019

$50,000

Study to Determine the Maximum Tolerated Dose and Recommended Phase 2 dose of ALA in Combination With Concurrent Chemoradiation in Head and Neck Cancer

Jeffrey Olsen, MD and Alexis Leal, MD

June, 2019

$50,000

Phase II Study of Induction FLOT Followed by Neoadjuvant Chemoradiation in Patients With Resectable Adenocarcinoma of the Esophagus Or Gastroesophageal Junction PRINCIPAL

Breelyn A. Wilky, MD

June, 2019

$50,000

An Open label, Phase II Efficacy Trial of Doxorubicin and Olaratumab in Combination With Dual Checkpoint Blockade Using Agen1884 and Agen2034 for Advanced or Metastatic Soft Tissue Sarcomas

Ross Camidge, PhD and Rustain Morgan, MD

May, 2019

$50,000

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers with Actionable Driver Mutations

Careye Cost, MD

May, 2019

$50,000

A Phase I/1b Study of Losartan in Combination With Sunitimib in the Treatment of Pediatric and Adult Patients with Relapsed or Refractory Osteosarcoma

Christine Fisher, MD,MPH  and Jennifer Diamond MD

May, 2019

$100,000

A randomized phase II Study of Anti-PD-1 and limited metastatic site radiation therapy versus anti-PD-1 alone for patients with microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) metastatic solid tumors

Elizabeth Kessler, M.D.

December, 2018

$70,000

Square wave Testosterone Therapy in castration resistant Prostate Cancer

Elissa Kolva, PhD

August, 2018

$50,000

Effect of Guided Imagery for Radiotherapy-Related Distress:  A Randomized Controlled Trial for Patients with Head and Neck Cancer

S. Lindsey Davis, MD

January, 2018

$50,000

Identifying biomarkers of immune-related toxicity in cancer Patients treated with immune checkpoint inhibitors; a pilot project

Clay Smith, MD and   Dan Pollyea, MD

September, 2017

$50,000

Phase I Trial of Arsenic Trioxide with Cyclophosphamide in Patients with Relapsed Refractory AML

Paul Maroni, MD

May, 2017

$50,000

A Phase 2 Study of Grape Seed Extract (GSE) Product I Asymptomatic Non-Metastatic Prostate Cancer Patients with Rising PSA

Sana Karam, MD

November, 2016

$50,000

A Dose Escalation Trial of Stereotatic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer